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Objectives: To use health economic modeling techniques to quantify and compare 
the clinical and economic outcomes associated with the use of subcutaneous inter-
feron beta-1a (scIFNβ 1a) vs. intramuscular interferon beta-1a (imIFNβ 1a) over 2 years 
in the management of relapsing forms of multiple sclerosis (MS) from a US health 
care payer perspective. MethOds: The 2-year decision analytic model was popu-
lated with IMS LifeLink Plus prevalence and treatment data, and clinical data from 
the EVIDENCE (EVidence of Interferon Dose-response: European North American 
Comparative Efficacy) study, a direct head-to-head comparison of 44 mcg scIFNβ 1a 
three times a week vs. 30 mcg imIFNβ 1a once a week. Relapse data from 16-month 
results were extrapolated for the 2-year model. Disease-modifying drug (DMD) costs 
were based on 2014 wholesale average cost with consideration of patient copay-
ment in the base case. The model was created with the ability to customize the rate 
of copayment as well as to incorporate contractual discounts, if desired. One-way 
sensitivity analyses were conducted on key parameters using alternate plausible 
values, including the rates of real-world DMD adherence. Results: For a hypotheti-
cal health plan with 1 million members, it is estimated that 911 patients with MS 
would be treated with DMDs. More relapses were avoided with scIFNβ 1a over 2 years 
(979) than with imIFNβ 1a over 2 years (778). The average cost-effectiveness of 44 mcg 
scIFNβ 1a was lower (more favourable) than the average cost-effectiveness of 30 mcg 
imIFNβ 1a ($123,854 vs. $148,749 per relapse avoided). Sensitivity analyses around 
model input values showed the model was robust and cost-effectiveness results 
were consistent. The model results are most sensitive to drug cost. cOnclusiOns: 
Cost-effectiveness assessment may facilitate the decision-making process in select-
ing MS treatments. Using the highest-quality clinical data (Level 1, head-to-head 
study, EVIDENCE), the cost-effectiveness of 44 mcg scIFNβ 1a was shown to be favour-
able compared with 30 mcg imIFNβ 1a.
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Objectives: To evaluate the cost-effectiveness of 44 mcg subcutaneous interferon 
beta-1a (scIFNβ 1a) and intramuscular interferon beta-1a (imIFNβ 1a) during the com-
parative and open-label extension phases of the EVIDENCE (EVidence of Interferon 
Dose-response: European North American Comparative Efficacy) study. MethOds: 
A decision analytic model from a US health care payer perspective was populated 
with 2-year data from the EVIDENCE study of imIFNβ 1a and 44 mcg scIFNβ 1a (com-
parative and open-label extension phases). EVIDENCE results showed that the annu-
alized relapse rate of 44 mcg scIFNβ 1a patients was 0.46 during the comparative 
phase and 0.34 during the open-label extension phase. The annualized relapse rate 
of imIFNβ 1a patients during the comparative phase was 0.64. imIFNβ 1a patients who 
switched to 44 mcg scIFNβ 1a for the open-label extension phase had an annualized 
relapse rate of 0.32. These data were used to model the cost-effectiveness of 44 mcg 
scIFNβ 1a and imIFNβ 1a patients during the comparative phase as well as for the 
combined comparative and open-label extension phases (for patients remaining 
on scIFNβ 1a throughout and for those switching from imIFNβ 1a in the comparative 
phase to scIFNβ 1a in the open-label extension). Disease-modifying drug (DMD) cost 
was based on 2014 wholesale average cost with consideration of patient copayment 
in the base case. Results: The cost-effectiveness for 44 mcg scIFNβ 1a and imIFNβ 1a 
during the comparative phase was $123,854 and $148,749 per relapse avoided, 
respectively. The cost-effectiveness of patients who remained on 44 mcg scIFNβ 1a 
throughout the study was $99,398 per relapse avoided, while the cost-effectiveness 
of imIFNβ 1a patients who switched to 44 mcg scIFNβ 1a for the open-label extension 
was $116,404 per relapse avoided. Sensitivity analyses showed that the model was 
robust and was most sensitive to DMD cost. cOnclusiOns: This decision analytic 
model evaluation shows that remaining on 44 mcg scIFNβ 1a and switching from 
imIFNβ 1a to 44 mcg scIFNβ 1a were cost-effective treatment strategies.
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Objectives: To assess the cost-effectiveness of Lacosamide (LCM) in the manage-
ment of epileptic partial onset seizures (POS) versus standard AED therapy in Greece, 
as well as its impact on the health care budget. MethOds: A cost-effectiveness 
model was developed simulating the treatment pathway of a hypothetical cohort of 
1000 patients over two years. A comprehensive literature search was conducted to 
identify local resource use data for medical, pharmaceutical and hospital treatment. 
Due to lack of relevant data, an expert panel with 8 neurologists was convened. The 
perspective was that of the Social Insurance Fund, and unit costs were taken from 
officially published sources (Ministry of Health and Social Insurance Fund). Primary 
and secondary analyses were carried out, in which the treatment algorithm was 
based on trial data and was adapted to the Greek setting, respectively. Deterministic 
and probabilistic sensitivity analyses were conducted to test the model’ results. In 
addition, a budget impact analysis (BIA) was carried out to estimate the annual 
cost of treating uncontrolled epileptic patients in Greece. Results: Treatment with 
LCM was shown to be dominant compared to standard therapy, as it is associated 
with 38 additional QALYs and reduced cost by € 410,024 and € 754,684 in the primary 
resource utilisation and the costs associated with health care management of MS 
in Slovakia and to provide a basis for cost-effectiveness evaluations. MethOds: 
Descriptive epidemiological data of 2,552 MS patients from 27 MS-centers across 
Slovakia were collected electronically and analyzed. In 152 selected patients fol-
lowed up in 2011-2012 in 34 MS centers, all types of health care services and costs 
were analyzed. These patients were randomly included in the study. Continuous 
variables were calculated using standard descriptive statistical methods. Results: 
77% of patients had the relapsing-remitting form of MS (RRMS); 60 % of patients 
were in EDSS 1-3, mean age of patients at the time of diagnosis was 32.3 (± 9.7) years, 
and 68% of patients were females. Total direct health care costs, DMT excluded, 
ranged from € 752 to EDSS 1 to € 2,839 to EDSS 7, being the lowest for EDSS9 (at 
€ 963). Costs for DMT ranged from € 8,584 for EDSS1 to € 13,026 in EDSS4, being lower 
for EDSS6 (€ 1,668) and none for EDSS7-9.67% patients were receiving 1st line DMT, 
and 14 % receiving 2nd line treatment. DMT was mostly applied in EDSS 2 (97%). 
The most frequently used DMTs were glatiramer acetate (20%), interferon beta-
1a IM (15%), natalizumab (9%) and fingolimod (5%). The most expensive grade 1/2 
adverse events were abdominal pain (46.62 € ), pain in joints, back and arms (39.35 € ). 
cOnclusiOns: This cross-sectional study determined the average annual direct 
cost per MS patient to be € 1,640; DMT excluded. As the EDSS increases, DMT costs 
decrease (except of EDSS1-2) and the costs of medical devices rise.
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Objectives: In Spain, Parkinson Disease Associations (PDA) offers a wide range of 
care services with partial and variable financial support from the government. The 
study objective was to estimate the costs of PDA services and to calculate the poten-
tial savings that they represent to the National Health System (NHS). MethOds: 
A survey conducted by the Federation of PDA collected information on their loca-
tion, number of members, type and use by patients of the offered services. Services 
were classified according to whether or not they were financed by the NHS, based 
on the existing national portfolio for reimbursed services. Weekly use was recorded 
and costs were calculated upon official rates (updated to € , 2014). Potential savings 
for the NHS were estimated by calculating the weekly cost associated to unfinanced 
services that were provided by the PDA. Results: 42 Spanish PDA that embraced a 
total of 11,420 patients participated in the study. From the 26 services offered, speech 
therapy (n= 41), physiotherapy (n= 39), cognitive stimulation (n= 23) and occupa-
tional therapy (n= 23) were the most frequently offered and used. The weekly cost 
associated to the provided services was € 655,219.87 [mean: € 15,980.97 (SD: 22,662.98)] 
per PDA. 53.8% of services were classified as potentially refundable by the NHS. Costs 
assaignable to potentially financed services represented 78.29%, reaching savings for 
the NHS of € 512,971.60/week. The cost of physiotherapy (27.3%) and of the adapted 
transport (21.3%) were the main components. Costs attributable to services not usually 
financed by the NHS accounted for 21.71% (€ 142,248.23), mostly attributable to cognitive 
stimulation costs (63.39%). cOnclusiOns: PDA offer valuable services to patients and 
carers and afford a major proportion of the costs of the supportive and complementary 
care of the disease. Their economic efforts imply great savings to the NHS in Spain.
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Objectives: To compare clinical outcomes (reduction in relapse number) and 
costs associated with multiple sclerosis (MS) treatment with one of the interferon 
β in the Czech Republic in five-year horizon based on development of neutral-
izing antibodies (NAbs) and patient non-adherence. Intramuscular (IM) interferon 
β -1a is characterized by very high adherence rate and low rate of NAbs produc-
tion. MethOds: Markov cohort model was developed with one-year cycle length. 
In the Czech Republic, patients with MS initiate treatment with one of the interferon 
β . NAbs-positive patients (in the model, NAbs are detected during the second year of 
treatment and thereafter) are switched/escalated to a different disease modifying 
drugs; DMD (glatiramer acetate, fingolimod, natalizumab). If patients experience 
two or more relapses during one year of treatment, they are escalated to fingoli-
mod or natalizumab. Adherence data, development of NAbs, relapse rate and costs 
were sourced from the literature. Results: One hundred patients, who initiated 
treatment with IM interferon β -1a, experienced 287 relapses over 5 years. Those, 
who started treatment with subcutaneous (SC) interferon β -1a and interferon β -1b, 
experienced by 15 and 19 relapses more. In one hundred patients, total cost of 
treatment with IM interferon β -1a was 6.4 million € . This was about 139-200 thou-
sand € less compared to SC interferon β -1a and interferon β -1b. Hence incremental 
cost-effectiveness ratio was -262 thousand € /relapse avoided and -285 thousand 
€ /relapse avoided. cOnclusiOns: Intramuscular interferon β -1a represents domi-
nant intervention in MS treatment, i. e. cost-saving treatment from payer’s perspec-
tive and simultaneously more efficacy intervention in terms of reduction in number 
of relapses due to better patient adherence and lower incidence of NAbs compare 
to the other interferons β in the Czech Republic. The one-way sensitivity analyses 
showed that results are the most sensitive to DMD costs and relapse rate.
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